Clinical Trial Update: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of SIM0237 alone or in combination with BCG in non-muscle-invasi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)
• SIM0237

Snippet

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Conditions: Non-Muscle-Invasive Bladder Cancer (NMIBC) | Phase 1 | Status: RECRUITING